We investigated whether coronary flow reserve (CFR) can be modified by tadalafil, a long-acting phosphodiesterase 5 (PDE5) inhibitor, in patients with documented coronary artery disease (CAD). CFR was non-invasively evaluated in 12 men with a positive history for erectile dysfunction (ED) and angiographically documented CAD, in the distal portion of the left anterior descending coronary artery, free from critical stenosis, with contrast enhanced echocardiography at time zero (T0). Then, after 20 mg tadalafil was orally administered CFR measurement was repeated after 2 h (T1) and after 24 h (T2). Doppler curves suitable for the analysis were obtained in all patients (CFR feasibility: 100%). The peak diastolic velocity after adenosine infusion increased from 71.3714.3 cm/s at T0 to 82.5724.0 at T1 (P ¼ NS) and to 89.5721.1 at T2 (P ¼ 0.0010). CFR after tadalafil increased significantly from 2.670.3 at T0 to 3.170.7 at T1 (P ¼ 0.0078) and a further increment was found at T2 (3.570.9; P ¼ 0.0010 vs T0). Our study shows that oral administration of tadalafil exerts a long standing, potentially beneficial effect on coronary microvasculature in patients with ED.
Introduction
Erectile dysfunction (ED), defined as the inability to achieve and maintain an erection sufficient for satisfactory sexual performance, is a frequent condition. 1 Coronary artery disease (CAD) and ED of vascular origin are frequently concomitant, [2] [3] [4] [5] [6] since they share the same risk factors, in particular smoking habits, diabetes, obesity, hypertension and low-serum high-density lipoproteins. Microvascular dysfunction due to endothelial damage lies at the basis of both conditions; 7 resulting in altered bioavailability of nitric oxide (NO), prostaglandins, angiotensin and endothelin, with consequent limited capacity for vasodilation and increase in intimal medial thickness, which leads to atherosclerotic degeneration of the arteries involved.
Phosphodiesterase 5 (PDE5) inhibitors work to improve ED by preventing the breakdown of cyclic guanosine monophosphate (cGMP), resulting in increased cellular content and consequent relaxation of smooth muscle cells in the arteries and arterioles of the corpus cavernosum of the penis. Sildenafil, vardenafil and tadalafil have been shown to be effective and safe in a broad population of men with ED, including patients with CAD. Since the enzyme PDE5 that they inhibit is present in smooth muscle cells of all systemic arteries and veins, these agents have the potential to impact the cardiovascular system. 8 As a whole, they are mild vasodilators with no effect on heart rate, minimal hemodynamic effects and only small additive decreases in blood pressure, even when they are combined with other antihypertensive medicines. For these reasons, PDE5 inhibitors have a substantial potential for utilization in the cardiovascular field not only with the aim of safely improving sexual capacity but also of modulating the vasoreactivity of the entire arterial bed.
Sildenafil was the first drug to be used, and therefore its cardiovascular effects have been the most frequently studied: this PDE5 inhibitor has been demonstrated to cause a slight reduction in arterial and pulmonary pressure, 9 in addition to small effects on systolic stroke volume and cardiac frequency, both in healthy subjects and CAD patients. [10] [11] [12] [13] Tadalafil, the latest PDE5 inhibitor released on the market, has a structure which differs substantially from its precursors, and confers a uniquely long half-life of 17.5 h making it suitable for long-term use.
14 As a matter of fact, it has been recently demonstrated that the use of this drug over a 4-week period, improves endothelial function in subjects with increased cardiovascular risk with a benefit that is sustained 2 weeks after discontinuing treatment. 15 The aim of this study was to evaluate the early and late effects of tadalafil on coronary flow reserve (CFR), measured by a non-invasive method-transthoracic echocardiography-in subjects with ED and angiographically documented CAD.
Materials and methods

Study subjects
The effects of tadalafil were studied in 12 men with CAD, aged 44-71 (mean age 60.879.4) years. All had demonstrated critical coronary artery stenosis in at least one vessel, but no lesions on the left anterior descending (LAD) artery; angiography preceded the evaluation by no more than 2 months. All subjects were considered to be in a clinically stable condition (chronic cardiac ischemia or previous myocardial infarction at least 2 months before evaluation), with a positive history of ED (difficulty in reaching and/or maintaining an erection, with a IIEF-5 questionnaire score p21). Patients requiring nitrate therapy were excluded, as were those with evidence of marked myocardial hypertrophy or diabetes. All the enrolled subjects, were taken statins, independently with the lipid status, and continued their normal therapy (ASA, b-blockers, ACE-inhibitors and so on), were appropriately informed as to the nature of the study and gave their informed consent for the study procedures.
The procedures followed are in accordance with the ethical standards of the Institutional Responsible Committee on human experimentation.
Study protocol
CFR was evaluated non-invasively in all patients in the distal portion of the LAD by contrast enhanced echocardiography (CE-TTE) at time zero and then 20 mg of tadalafil were administered per os. CFR measurement was repeated 2 h (T1) and 24 h (T2) after drug administration.
As previously described in detail, 16, 17 to assess CFR a complete two-dimensional M-mode echo Doppler (spectral and color) study was performed in all patients both before and after intravenous echocontrast infusion, on an Acuson Sequoia ultrasound unit (C256 chocardiography System, Acuson Siemens) using a broad-band transducer with second-harmonic capability (3V2c). Once the routine echo Doppler examination was completed, CFR was evaluated using contrast-enhanced transthoracic Doppler before and after adenosine infusion. We evaluated CFR in the LAD with transthoracic Doppler (CE-TTE) during a 5-min adenosine infusion (140 mg/kg/min; Adenoscan, Sanofi-Synthelabo, Berlin, Germany). When the PW Doppler pattern was not clearly detectable, we used a Doppler signal contrast enhancer Levovist (Schering AG, Berlin), infused with a controlled-infusion pump (IVAC P4000 Anaesthesia Syringe pump) at a concentration of 300 mg/ml, and an infusion rate of 1 mg/min. Blood pressure and electrocardiogram were recorded at rest and every minute during adenosine infusion. Cardiac medications were not interrupted before adenosine infusion, although methylxanthine-containing medications were withheld 48 h before the study. Beverages containing methylxanthine substances (cola, tea, coffee and so on) were prohibited for 24 h before the study.
CFR in the LAD was calculated by one experienced echocardiographer-who was blind to the scope of the study and to the presence or absence of a control group, but not to the sequence of the measurements-as the ratio of peak diastolic velocity during hyperemia over peak diastolic velocity at baseline. For each parameter, the three highest values were averaged. M-mode and two-dimensional echocardiography and pulsed wave Doppler were used to evaluate cardiac chamber and valve morphology and function. 
Statistical methods
Results
Hemodynamics measurements are shown in Table 1 systolic and diastolic blood pressures as long as heart rates did not change significantly, 2 and 24 h after oral administration of tadalafil, compared to baseline.
Doppler curves suitable for analysis were obtained in all patients (CFR feasibility: 100%): as expected, Effects of tadalafil in men with ED and CAD F Bellotto et al baseline CFR measurements revealed a normal pattern in all study subjects. Peak diastolic velocity after adenosine infusion increased from 71.37 14.3 cm/s at T0 to 82.5724.0 at T1 (P ¼ 0.082) and to 89.5721.1 at T2 (P ¼ 0.0010). CFR after tadalafil increased significantly from 2.670.3 at T0 to 3.170.7 at T1 (P ¼ 0.0078) and a further increment was found at T2 (3.570.9; P ¼ 0.0010 vs T0) (Figure 1 ).
Discussion
The potential to increase CFR by PDF5 inhibitors is extremely interesting not only because coronary patients can use the drug safely, but also with a therapeutic purpose beyond that of simply treating ED, as suggested by Rosano et al. 18 in combination with trimetazidine, sildenafil was superior to nitrates in controlling episodes of myocardial ischemia during sexual activity in CAD patients.
Our study shows that oral administration of tadalafil exerts a long acting, potentially beneficial effect on coronary microvasculature in patients with ED. In agreement with Herrmann et al., 12 we found no differences in hemodynamics after tadalafil administration, with the same slight reduction of basal coronary flow velocities, followed by a significant increase after adenosine infusion. The increase of CFR after tadalafil in our patients cannot be attributed to hemodynamic variations, since heart rate and mean aortic pressure were not significantly different before or after tadalafil, either in basal condition or after adenosine infusion (Table 1) ; moreover, in previous studies we demonstrated the capacity of non-invasive CFR detected by Doppler echocardiography to be a reliable marker of coronary microvascular impairment in CAD and other cardiac diseases. [19] [20] [21] This suggests that tadalafil can induce significant coronary microcirculatory vasodilatation, by the observation of nonsignificant changes in basal coronary flow velocity in the absence of flow limiting stenosis of the epicardial vessels. Our study did not attempt to assess the side effects of the drug, but to reveal a potentially long-acting, beneficial effect on coronary microcirculation in patients with known CAD. Herrmann et al.
12 demonstrated the effect of a PDE5 inhibitor on CFR, assessed with an intracoronary Doppler guidewire in 25 coronary arteries-most of them with significant stenosisand 12 arteries without stenosis as controls, after 100 mg sildenafil administered orally (mean time between measurements, approximately 60 min). They found a global increase of 13% in CFR after sildenafil, although it was lower in the severely stenosed arteries than in the reference arteries (1.2670.26 vs 2.1970.44, Po0.05). To exclude the effect of coronary stenosis, which may affect CFR due to increased epicardial resistance, we studied only patients without critical stenosis on LAD, as determined by coronary angiography and confirmed by normal CFR values at time zero. In addition, the further improvement after tadalafil cannot be attributed to individual variations in CFR, because reproducibility in assessing CFR had previously been assessed in our laboratory and only revealed a small range of inter-test variability (70.3). Effects of tadalafil in men with ED and CAD F Bellotto et al Halcox et al. 22 measured the acute effect of sildenafil on resting coronary vascular tone in 24 patients 45 min after 100 mg oral sildenafil, and observed an epicardial coronary artery vasodilatation induced by the drug. In our study, the increase in CFR induced by tadalafil represents the first direct demonstration of the capacity of this PDE5 inhibitor to modulate coronary arteriolar resistance in patients with known CAD, with an effect that persists over time. In fact, in our patients, a mean increase in CFR 2 h after tadalafil administration was confirmed ( þ 20.8% with respect to CFR at baseline) which reached statistical significance (P ¼ 0.0078); at 24 h, the effect on CFR not only persisted but was further increased ( þ 35.6% with respect to baseline; P ¼ 0.0010) confirming the long half-life of this drug.
Dietz et al. 23 assessed CFR in the left LAD in 21 diabetics with ED at baseline and 1 h after 50 mg sildenafil: baseline CFR was at the lower level of the normal range and decreased insignificantly after sildenafil administration, probably due to the severe microvascular and endothelial dysfunction known to occur in diabetic patients. 24 Instead, our patients were not affected by insulin-dependent diabetes mellitus and had a normal baseline CFR, which increased after administration of the drug, demonstrating not only the absence of coronary critical stenosis but also a normal coronary microvasculature response to hyperemia-stimulated expression of a preserved endothelial function.
The possibility of increasing CFR in subjects with CAD, even if only in vessels free of critical lesions, with drugs used for the treatment of ED, makes it possible to imagine their use outside the realm of sexual impotence. The regional increase in CFR, induced by tadalafil and prolonged over time, may increase coronary microvasculature blood supply, possibly improving myocardial ischemia in CAD. These preliminary data suggest the usefulness of further longitudinal studies, to evaluate the real impact of improved CFR exerted by tadalafil on myocardial metabolism and contractile function and on clinical outcomes in patients with CAD.
